News

Home / Archive by category "News"

OCV Partners Participates in Finch Therapeutics’ Oversubscribed $90 Million Financing to Advance its Pipeline of Investigational Oral Microbiome Drugs

Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis B

Somerville, MA, September 17, 2020 – Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today an oversubscribed $90 million Series D financing.

OCV Partners participated in the round alongside new investors including Baupost Group, Humboldt Fund, MSD Capital, MSD Partners, Octave Group, and OMX Ventures, along with support from other existing investors, including Avenir Growth Capital, Shumway Capital, SIG, SymBiosis, TPTF, and Willett Advisors.

“We are delighted to have the support of this strong syndicate to advance our platform and pipeline,” said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. “The microbiome field is at an exciting inflection point, with recent positive clinical data from our trial in recurrent C. difficile and other clinical data suggesting that microbiome drugs may become the next major therapeutic class to transform patient care.”

“This additional funding positions us well for our next stage of development,” said Greg Perry, Chief Financial Officer of Finch Therapeutics. “In addition to advancing our lead candidate CP101 for recurrent C. difficile, we look forward to rapidly evaluating CP101 for the many other conditions linked to microbiome disruption, starting with a trial in chronic hepatitis B.”

Finch will use the proceeds from the financing to advance CP101 through the final stages of clinical development and regulatory submission in recurrent C. difficile infection (CDI), and to advance its platform and pipeline, including the initiation of Phase 1b studies evaluating FIN-211 for autism spectrum disorder (ASD) and CP101 for chronic hepatitis B (HBV).

“By starting their discovery process with insights mined from clinical data, Finch is pioneering a new and very promising approach to drug discovery,” said Nick Haft, Managing Director of OMX Ventures. “Recurrent C. difficile is only the tip of the iceberg, with dozens of proof-of-concept human microbiota transplantation studies demonstrating the potential of this approach for a wide variety of indications. With their platform, Finch is uniquely positioned to translate many of these exciting insights into promising new microbiome therapies.”

The financing builds on recent progress by Finch, with its lead candidate CP101, an investigational oral microbiome drug designed to deliver the full diversity of a healthy gut microbiome, meeting its primary efficacy endpoint for the prevention of recurrent CDI in a large, placebo-controlled trial earlier this year. Finch also recently announced the initiation of a program to evaluate CP101 for the treatment of chronic HBV, building off pre-clinical and clinical studies suggesting that delivery of a complete microbiome may drive viral clearance through stimulation of the innate immune response (1-4). Finch’s proprietary pipeline also includes FIN-211, an investigational oral microbiome drug initially targeting the treatment of children with ASD that suffer from serious gastrointestinal (GI) symptoms. FIN-211 is designed to re-establish a normal microbiome composition and function, building off pre-clinical and clinical studies suggesting that GI and behavioral symptoms may be linked to a disrupted microbiome (5-8). In partnership with Takeda Pharmaceuticals, Finch is also developing investigational oral microbiome drugs composed of rationally-selected strains designed to target specific mechanisms underlying the pathogenesis of inflammatory bowel disease. Finch’s first program with Takeda is focused on the development of FIN-524 for ulcerative colitis. After achieving key pre-clinical milestones with FIN-524, Finch and Takeda expanded their partnership to include the development of FIN-525 for Crohn’s disease.

About OCV Management LLC
OCV Management, LLC is a Los Angeles based investment firm co-founded by Richard Ressler and co-managed with Hemi Zucker, Managing Principal. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of over 22 years. OCV invests in companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit www.ocvpartners.com.

About Finch Therapeutics
Finch Therapeutics is developing novel microbiome drugs to serve patients with serious unmet medical needs. Finch’s Human-First Discovery® platform enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. Finch’s platform uniquely enables development of both complete microbiome communities and rationally selected consortia to restore microbiome functionality and resolve conditions driven by dysbiosis, or disruption of the microbiome. Finch’s lead program, CP101, is an investigational microbiome drug with Fast Track and Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile infection. The company is also developing FIN-211 for the treatment of children with autism spectrum disorder and CP101 for the treatment of chronic hepatitis B. The company has a strategic partnership with Takeda Pharmaceuticals focused on the development of microbiome drugs for inflammatory bowel diseases.

Media Contact:
Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412

Investor Contact:
Greg Perry
ir@finchtherapeutics.com

  1. Ren et al. Fecal microbiota transplantation induces hepatitis B virus e‐antigen (HBeAg) clearance in patients with positive HBeAg after long‐term antiviral therapy. Hepatology 2017.
    2.  Xie et al. Faecal microbiota transplantation induced HBSAG decline in HBEAG negative chronic hepatitis B patients after long-term antiviral therapy. Gut 2018.
    3. Chauhan et al. Fecal microbiota transplantation in hepatitis b e antigen-positive chronic hepatitis b patients: a pilot study. Dig Dis Sci 2020.
    4.  Chou et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. PNAS 2015.
    5.  Kang et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 2017.
    6. Kang et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Scientific Reports 2019.
    7. Ning et al. Efficacy analysis of fecal microbiota transplantation in the treatment of 2010 patients with intestinal disorders. China J Gastrointest Surg 2019.
    8. Sgritta et al. Mechanisms underlying microbial-mediated changes in social behavior in mouse models of autism spectrum disorder. Neuron 2018.

 

SafeBreach Raises $19 Million to Expand Channels, Accelerate Product Development

Experiencing rapid customer growth, the industry’s leading provider of breach-and-attack simulation will use the funding to accelerate the development of new product capabilities and services, expand strategic partnerships and grow its channel relationships with major MSSPs.

Sunnyvale, CA – April 15, 2020 — SafeBreach, provider of the leading breach-and-attack simulation (BAS) platform to validate security controls, visualize security risk and prioritize remediations, today announced that it has secured $19 million in Series-C funding. The round brings the total amount of capital raised by SafeBreach to over $50M. OCV Partners led the round with participation by previous investors Sequoia Capital, Deutsche Telekom Capital Partners, DNX Ventures, Hewlett Packard Pathfinder, and PayPal. SafeBreach will use the additional funding to accelerate product development to address the growing needs of customers and to accelerate sales channel and partnership growth on a global scale. In addition, the company will add a suite of new services for its rapidly growing base of customers who have embedded SafeBreach BAS into their daily operations as a means to continuously validate security posture and optimize configurations of existing security tools.

“In a continually changing threat environment, most enterprise security groups have responded by buying more security products and hoping that will make them more secure. But hope is not a viable strategy,” says Guy Bejerano, co-founder and CEO of SafeBreach. “Instead, CISOs and security teams need to improve their security stance on an ongoing basis and avoid the misconfigurations and security lapses of their existing security controls that make possible the vast majority of serious security incidents today.”

The funding round comes after rapid customer growth and usage during the past two years. In 2018 and 2019, dozens of multi-billion dollar entities in financial services, healthcare, manufacturing, telecommunications, retail and other industries adopted breach and attack simulation as part of their core strategy to validate controls, improve security posture and reduce business risk. They committed to SafeBreach as their core platform for attack simulation, security risk visualization and prioritization. During the past 12 months, the volume of monthly simulations running on SafeBreach BAS platforms worldwide has grown at a triple digit rate, eclipsing 1.5 billion monthly simulations at its peak. During this period, SafeBreach has aggressively expanded its product offerings and integrations into high-demand areas including cloud-native security, risk-based vulnerability management and, most recently, security validation for remote workforces.

“The explosive growth of cyberattacks, combined with the increasing complexity of managing IT infrastructure, creates a pressing need for continuous attack simulation. In addition, overstretched security teams need the ability to visualize their entire attack surface, receive guidance on remediation
decisions, and ultimately reduce business risk,” says Hemi Zucker, Managing Principal at OCV Partners. “We are impressed with the rapid growth and quality of SafeBreach customers, and believe that SafeBreach is uniquely positioned to address those challenges, and to change the game for IT security.”

Key Additions to Board of Directors and Advisory Board

Hemi Zucker, Managing Principal at OCV Partners, will be joining the SafeBreach board of directors. Zucker has deep experience growing technology companies. He formerly served as the CEO of cloud services and publishing company J2 Global (NASDAQ:JCOM), where he grew the company from founding to a $4.5 billion market capitalization.

“Hemi Zucker will be a great asset to SafeBreach’s Board of Directors and ultimately to our customers,” says Guy Berejano. “He has an outstanding track record of how to drive and sustain rapid growth to achieve dominant market position.”

In addition, SafeBreach has added key industry experts and practitioners to its Advisory Board including: Christine Herman, VP and Head of Operational Assurance at Morgan Stanley, Yaron Levi, CISO of Blue Cross Blue Shield Kansas City, Dr. Sunil Lingayat, Chief of Cybersecurity Strategy and Technology atT-Mobile, and Peter Liebert, former CISO of the State of California.

Expanding Strategic Partnerships and Growing Channel Relationships

In recognition of the continued product innovation and growing customer traction achieved by SafeBreach, major cybersecurity companies, including Microsoft and IBM, top cyber consulting firms like Deloitte and leading integration partners, including Blackberry Cylance and SentinelOne, have partnered with the company to deliver automated continuous attack simulations to their customer base of Fortune 500 organizations.

Expanding these partnerships and channels will dramatically broaden the market reach of SafeBreach. These initiatives will also increase awareness of the key role that automated BAS plays in forward-thinking cybersecurity strategies that address the dynamic nature of attacks as well as the growing risk of self-inflicted harm due to improper and poorly validated security control configurations.

About SafeBreach

SafeBreach is the world’s most widely used breach-and-attack-simulation platform. The company’s patented platform provides a near real-time “hacker’s view” of an enterprise’s security posture to proactively predict attacks, validate security controls and improve security operations center (SOC) analyst response capabilities. SafeBreach automatically and safely executes thousands of breach methods validating network, endpoint, cloud and email security controls by leveraging its extensive and growing Hacker’s Playbook™ of research and real-world investigative data. Headquartered in Sunnyvale, California, the company is funded by Sequoia Capital, Deutsche Telekom Capital Partners, OCV Partners, DNX Ventures, Hewlett Packard Pathfinder, PayPal and investor Shlomo Kramer. For more information, visit www.safebreach.com or follow us on Twitter @SafeBreach.

About OCV Management LLC

OCV Management, LLC is a Los Angeles based investment firm co-founded by Richard Ressler and co-managed with Hemi Zucker, Managing Principal. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of over 22 years. OCV invests in companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit www.ocvpartners.com.

OCV Partners Co-leads By Heart’s $70M Series A Financing Ahead of First Product Launch in 2021

Lead Investors Include Polaris Partners, D1 Capital Partners, and OCV Partners in the Over-Subscribed Round; Former Pfizer Baby Nutrition Leader, as well as Former CEO of J2 Global (What to Expect, BabyCenter and Everyday Health) Join the ByHeart Board of Directors

NEW YORK, April 14, 2020 (Newswire.com)  — ByHeart, a company focused on the evolution of one of our most fundamental nutrition markets – infant & baby – announced the recent closing of $70 million in Series A funding led by Polaris Partners, D1 Capital Partners, and OCV Partners, in advance of its first infant formula product launch in 2021. Additional investors in the round include Red Sea Ventures, Sean Parker, and existing investors including Bellco Capital and affiliates of Two River.

Co-founded by Mia Funt and Ron Belldegrun in 2016, ByHeart grounds innovative products in next-to-nature quality, leading nutrition science, and production transparency, and strives for its baby foods and formulas to sit at the forefront of immune, cognitive, digestive and microbiome health.

“We founded ByHeart to unlock real choice for parents in a moment that can be overwhelming: formula and baby food products are not optional for most parents – they are crucial – which is why they must be accessible, uncompromised, holistic sources of nutrition. We want parents to feel engaged with what their baby eats and empowered as they create a foundation of health for their babies’ lives to follow,” explained Ron Belldegrun, CEO of ByHeart, and newly a father himself.

With ownership of manufacturing and research & development facilities, ByHeart seeks to maximize both quality and safety for its consumers, and is in a unique position to circumvent significant channel markups and invest those savings into what truly matters: hand-picked ingredients, small batch blending, evolved nutrition science, rigorous quality controls, and ultimately an elevated consumer experience. This experience will position community and education as paramount to transforming the baby nutrition category.

Mia Funt, ByHeart President and mother of two, said, “Feeding is one of the very first decisions we make as parents. It’s incredibly intimate and personal, and often defines how successful we feel in a completely new role. At ByHeart, we believe in feeding freedom, which means that every parent has access to the very best choices, whenever and wherever they need them.”

After three years of building and developing its products, team and facilities, as well as a network of nutrition, regulatory and parenting experts, the company is conducting a multi-site, infant-growth monitoring clinical study in accordance with the U.S. Food and Drug Administration’s rigorous requirements, to support ByHeart’s first product launch in 2021. The Series A investment evidences investors’ confidence in the company’s considered approach.

ByHeart welcomes representatives from two of the lead Series A investors onto its Board of Directors: Amy Schulman and Hemi Zucker. Ms. Schulman, Managing Partner at Polaris Partners, previously led Pfizer Baby Nutrition prior to its sale to Nestle, and helmed Pfizer Consumer Health’s business. Mr. Zucker is Managing Principal of OCV and a founding member of J2 Global, owner of the leading parenting and health sites What to Expect, Baby Center and Everyday Health. Mike Tully joins the board as an observer on behalf of D1 Capital Partners, a $10 billion global investment firm founded by Dan Sundheim whose private investments include Sweetgreen, Stripe and Instacart. These new Board members join biotechnology entrepreneur and Co-Founder of Bellco Capital, Arie Belldegrun, M.D., FACS, as well as Josh Bradley, Chief Investment Officer of Bellco Capital, Joshua Kazam, Co-Founder and Partner of Two River Group, and Guy Oranim, Co-Founder and Chief Executive Officer of First Media.

Ms. Schulman explained ByHeart’s distinction: “The impressive blend of pediatric professionals, nutrition scientists, proprietary blendmasters, and content media visionaries behind ByHeart position the company uniquely to invigorate the existing baby nutrition market and serve as a partner for all parents to embrace their babies’ health in more proactive ways.”

###

Founded in 2016, and based in New York City with facilities in Pennsylvania, ByHeart produces evolved formula and food products to support babies’ nutrition and parents’ peace of mind.
Find out more at www.byheart.com.
Press contact: Elyssa Dimant (elyssa@byheart.com)

About OCV Management LLC

OCV Management, LLC is a Los Angeles based investment firm co-founded by Richard Ressler and co-managed with Hemi Zucker, Managing Principal. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of over 22 years. OCV invests in companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit www.ocvpartners.com.

Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection

– 206 patients randomized at 51 centers in a multinational, placebo-controlled trial
– Topline data expected at the end of Q2 2020

Somerville, MA (January 8, 2020) — Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome therapeutics company, announced today that it has completed enrollment in PRISM3, its multi-center, placebo-controlled Phase 2 clinical trial evaluating CP101. CP101 is an oral, potentially first-in-class microbiome therapeutic that has been granted Fast Track and Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA), and is being investigated for the prevention of recurrent C. difficile infections (CDI).

A total of 206 participants were randomized in PRISM3 at 51 sites across the U.S. and Canada. Finch expects to report topline preliminary efficacy and safety results at the end of the second quarter of 2020. PRISM3 could serve as one of two pivotal trials required for product registration or, based on recent communication with the U.S. FDA, it may provide the data necessary to support registration without a second pivotal trial if a sufficient level of statistical significance is demonstrated in PRISM3.

“We are thrilled to have reached this important milestone on our journey to alleviate the suffering caused by recurrent CDI,” said Mark Smith, CEO of Finch. “We are excited to share the results of this landmark trial as we believe that positive PRISM3 results will not only impact the future treatment of recurrent CDI but will also validate the potential of microbiome therapeutics, paving the way for further development of potentially transformative therapies for a wide range of conditions linked to the microbiome.”

“We are deeply grateful to everyone that made it possible to reach the ambitious enrollment goals we set for the PRISM3 trial,” said Dr. Zain Kassam, CMO of Finch. “This achievement was enabled by each individual that participated in PRISM3 and the support of incredibly dedicated principal investigators and their clinical research staff. Alongside our collaborators, we will continue to work with urgency to develop an approved microbiome therapeutic for patients battling recurrent C. difficile infections.”

Finch plans to continue enrolling patients in an open-label safety study, PRISM-EXT, at sites participating in PRISM3. PRISM-EXT will allow eligible patients with recurrent CDI to have continued access to CP101 and will enable Finch to expand its safety database for CP101.

About CP101

CP101 is an investigational Full-Spectrum Microbiota® (FSM®) therapy delivered in an oral capsule. Finch’s FSM therapies contain a diverse community of microbiota that are sourced from rigorously screened human donors and processed into capsules in accordance with Good Manufacturing Practice (GMP) standards. CP101 is designed to restore colonization resistance and prevent recurrence of C. difficile infection by delivering a diverse microbial community. CP101 has been awarded Fast Track and Breakthrough Therapy designation by the U.S. FDA. In August 2019, Finch raised $53 million in a Series C financing to advance CP101, its lead therapeutic candidate, and its pipeline of investigational therapies for other conditions linked to a disrupted gut microbiome.

About C. difficile Infection

Clostridioides difficile (C. difficile) is one of the top five most urgent antibiotic-resistant bacterial threats and the most common healthcare-associated infection according to the Centers for Disease Control. More than 450,000 individuals in the U.S. experience a CDI each year, with 20% of individuals suffering from recurrent CDI (i.e. more than one episode of CDI). CDI contributes to more than 29,000 deaths and drives more than $6 billion in healthcare costs per year in the U.S. alone.

About Finch

Finch Therapeutics Group, Inc. (Finch) is developing novel microbiome therapeutics to serve patients with serious unmet medical needs. Built on 30 years of translational research at OpenBiome, MIT, University of Minnesota and the Center for Digestive Diseases, Finch uses Human-First Discovery® to develop therapies from microbes that have demonstrated a clinically significant impact on patient outcomes. Finch is unique in having both a donor-derived Full-Spectrum Microbiota® (FSM®) product platform and a Rationally-Selected Microbiota® (RSM®) product platform based on microbes grown in pure culture. Finch’s lead program, CP101, is an investigational FSM product with Fast Track and Breakthrough Therapy designation from the FDA for the prevention of recurrent C. difficile infection. Finch also has Fast Track designation from the FDA for a program to develop a microbiome therapeutic for children with Autism Spectrum Disorder.

Finch’s RSM platform employs machine-learning to mine Finch’s unique clinical datasets, reverse engineering successful clinical experience to identify the key microbes driving patient outcomes. Finch has a strategic partnership with Takeda Pharmaceuticals to develop FIN-524, an investigational RSM product for ulcerative colitis. Finch and Takeda are also utilizing Finch’s platform to target Crohn’s disease, another form of inflammatory bowel disease.

Finch is using a rich foundation of clinical data to advance its pipeline, leveraging proof-of-principle results to evaluate target indications and inform the design of this new therapeutic class.

CP101 is not approved in any country. The FDA’s Fast Track and Breakthrough Therapy designations do not constitute or guarantee future approval or alter the standards for approval.

Full-Spectrum Microbiota, FSM, Rationally-Selected Microbiota, RSM, and Human-First Discovery are trademarks of Finch Therapeutics Group, Inc.

MediaContact
Gabriella Linville-Engler
media@finchtherapeutics.com

Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas

Somerville, MA (August 22, 2019) — Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors.

Finch will use the Series C proceeds to advance its pipeline of novel microbial therapies, including CP101, a Full-Spectrum Microbiota® (FSM®) therapy delivered in an oral capsule that is designed to contain a diverse community of microbiota and restore a balanced microbiome. CP101 is currently being evaluated for the prevention of recurrent C. difficile infections (CDI) in Finch’s PRISM3 trial, a potentially pivotal clinical study. Compelling results from the PRISM3 trial may be sufficient to support FDA approval, based on recent communications with the agency.

The Series C proceeds will also enable Finch to accelerate the development of its FSM therapy for Autism Spectrum Disorder (ASD). ASD is a developmental disorder characterized by behavioral symptoms and often accompanied by gastrointestinal (GI) symptoms. Studies suggest that GI and behavioral symptoms may be linked to a disrupted microbiome. Finch is supporting an actively enrolling, Phase II, investigator-initiated clinical study (NCT03408886) evaluating the safety and efficacy of its FSM therapy in adults with ASD. Finch has also received FDA Fast Track designation for its pediatric ASD program.

Beyond CDI and ASD, Finch is continuing to expand its pipeline of microbiome-based therapeutics, including a pre-clinical Rationally-Selected Microbiota® (RSM™) program in Inflammatory Bowel Disease (IBD), in partnership with Takeda Pharmaceuticals.

“We are thrilled that this additional funding, coupled with the recent Breakthrough Therapy designation we received from the FDA, will enable us to accelerate our efforts to provide a new therapy to patients battling recurrent C. difficile,” said Mark Smith, CEO of Finch. “We also look forward to advancing our investigational therapies for ASD, IBD and other conditions linked to a disrupted microbiome.”

CP101 is not approved in any country. The FDA’s Breakthrough Therapy and Fast Track designations do not constitute or guarantee future approval and do not alter the standards for approval.

About Finch Therapeutics

Finch Therapeutics Group, Inc. (Finch) is developing novel microbial therapies to serve patients with serious unmet medical needs. Built on 30 years of translational research at OpenBiome, MIT, University of Minnesota and the Center for Digestive Diseases, Finch uses Human-First Discovery™ to develop therapies from microbes that have demonstrated clinically significant impacts on patient outcomes. Finch is unique in having both a donor-derived Full-Spectrum Microbiota® (FSM®)  product platform and a Rationally-Selected Microbiota® (RSM™) product platform based on microbes grown in pure culture. Finch’s lead program, CP101, is an investigational FSM  product for prevention of recurrent C. difficile  infections. Finch’s RSM platform employs machine-learning to mine Finch’s unique clinical datasets, reverse engineering successful clinical experience to identify the key microbes driving patient outcomes. Finch is using a rich foundation of clinical data to advance its pipeline, leveraging proof-of-principle results to evaluate target indications and inform the design of this new therapeutic class.

Full-Spectrum Microbiota, FSM, Rationally-Selected Microbiota, RSM, and Human-First Discovery are trademarks of Finch Therapeutics Group, Inc.

About Recurrent Clostridium difficile Infection (CDI)

Clostridium difficile infection (CDI) is the most common hospital-acquired infection in the United States. CDI is a bacterial infection that causes severe diarrhea and GI distress, and can be life-threatening. CDI often results from disruption of a patient’s microbiome following antibiotic use. Over 500,000 Americans are infected every year, with 25% or more of patients suffering a recurrence, or return of symptoms, resulting in substantial morbidity and healthcare costs.

About Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder (ASD) is characterized by deficits in communication and social interaction and restricted/repetitive behaviors that interfere with daily living. Many individuals with ASD also suffer from chronic gastrointestinal symptoms such as constipation and diarrhea. Studies suggest ASD may be linked to a disrupted microbiome. Approximately 1 in 59 children in the US is diagnosed with ASD. There are no FDA-approved therapeutics that address the core symptoms of ASD.

About OCV Management LLC

OCV Management, LLC is a Los Angeles based investment firm co-founded by Richard Ressler and co-managed with Hemi Zucker, Managing Principal. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of over 22 years. OCV invests in companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit www.ocvpartners.com.

Press Contact: Gabriella Linville-Engler
media@finchtherapeutics.com

Museum of Ice Cream Founders Launch Figure8 with Series A to Transform How Millennials and Gen-Z Connect With Spaces and Each Other

Funding led by Elizabeth Street Ventures, Maywic Select Investment, and OCV Partners

New York, NY (August 14, 2019) — Founders of Museum of Ice Cream, Maryellis Bunn and Manish Vora, launch Figure8, an experience-first development company. Figure8, now parent company of Museum of Ice Cream, completed its first close of a $40M Series A round at a $200M valuation led by consumer venture capital firms Elizabeth Street Ventures, Maywic Select Investment, along with strategic investments from venture fund OCV Partners.

“We created Figure8 to chart the future of how Millenials and Gen Z will want to spend their time. Over the past 3 years building Museum of Ice Cream, we have learned so much from our guests and gained endless insight. Globalization and technology have made the world smaller, yet people are more lonely than ever” said Maryellis Bunn, 27-year-old Co-Founder of Figure8 and Museum of Ice Cream. “I want to inspire people around the world with what I call experiums, emotional and transformative moments and spaces for people to reconnect with themselves and those around them.”

Since Museum of Ice Cream’s conception in 2016, it has catapulted a cultural phenomenon and ignited an entire experiential industry. The company has welcomed over 1.5M visitors to locations in Los Angeles, New York, Miami, and San Francisco. The brand launched an ice cream line sold at Target and created high-profile partnerships with Platinum Card by American Express, a makeup collection with Sephora, and a kids clothing line at Target.

“Museum of Ice Cream receives an overwhelming amount of requests from companies asking us to design branded experiums for them,” said Manish Vora, Co-Founder of Figure8. “Now we can answer this need and more. Figure8 will expand internationally, rolling out a new Museum of Ice Cream location each quarter while also launching new Figure8 brands and working on commissioned special projects. ”

Will McClelland, Co-founder of Elizabeth Street Ventures, joins the board of Figure8. “Figure8 and Museum of Ice Cream are built on core tenets of imagination, connection and creativity. These are things that are part of a shared human experience and so important to how we live and improve our daily lives,” says, McClelland. “Elizabeth Street is incredibly excited to support this endeavor and bring memorable experiences to people around the world.”

Frederic Mayerson, Chairman & Managing Partner of Maywic Select Investments said, “Museum of Ice Cream has redefined the expectations and influence of experiences with explosive growth. Figure8’s team has a unique ability to tap into the mindset of today’s customers and will continue to revolutionize the industry it has helped create.”

Figure8 currently has a team of 35 at its NYC headquarters and is growing its senior leadership for global expansion. Andrew Lumsden joins as SVP of Operations bringing over 20 years of experience working with food, beverage, and hospitality brands including Zuma, The Ace Hotel, The Spotted Pig, Noho Hospitality and Stephen Starr. Peter Sun joins the team as Vice President, Brand & Marketing with over a decade of experience building global brands including P&G, Unilever, Hilton, LVMH, HSBC, Volvo, and more.

About FIGURE 8

Figure8 is an experience first company that creates experiums, places outside of distraction, away from expectation, and beyond inhibition to get lost and found. We invite guests to take a moment to recognize, realize, and reignite relationships with the people and places around them. The potential is limitless.

About OCV Management LLC

OCV Management, LLC is a Los Angeles based investment firm co-founded by Richard Ressler and co-managed with Hemi Zucker, Managing Principal. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of over 22 years. OCV invests in companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit www.ocvpartners.com.

Press Contact: press@figure-8.co

OSSIO Receives FDA 510(k) Clearance for OSSIOfiber® Hammertoe Fixation System

Complete Offering of Implant Sizes and Shapes Provides Surgeons and their Patients an Intelligent Bone Regeneration Alternative to Metal Fixation

WOBURN, Mass — OSSIO, Inc., an orthopedic fixation company, today announced that its OSSIOfiber® Hammertoe Fixation System has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis and bone grafts. These novel bio-integrative implants with disposable, sterile instrumentation now come in three sizes, with both straight and angled configurations for better customization among various patient anatomies.

The OSSIOfiber® Bone Pin Family initially received 510(k) market clearance from the FDA in January 2019 and was later commercialized as part of a limited market release for use in the foot and ankle segment for the treatment of common forefoot conditions, such as hammertoe, where hardware removal surgeries are prevalent. The OSSIOfiber® Hammertoe Fixation System comprises the company’s breakthrough OSSIOfiber® Intelligent Bone Regeneration Technology, a new category of fixation material that combines unparalleled mechanical strength and natural bone healing in a nonpermanent implant. Made from a proprietary natural mineral fiber matrix, its bio-integrative material properties provide surgeons with a more biologically friendly way to restore patient stability and mobility while leaving nothing permanent behind.

“With more than 500 successful hammertoe repairs conducted to date utilizing the OSSIOfiber® Hammertoe Implant, along with the completion of our European multi-center study confirming the overall safety and positive performance of our proprietary technology, confidence in achieving excellent clinical outcomes and high surgeon and patient satisfaction continues to grow,” said Brian Verrier, CEO, OSSIO. “Launching the broader hammertoe offering along with several other OSSIOfiber® product platforms over the next year will serve a broader orthopedic fixation market that aspires to avoid the risks, costs and trade-offs associated with permanent implants. We are dedicated to providing surgeons and their patients with a more intelligent way to restore, regrow and renew bone.”

In 2019, OSSIO completed enrollment in its European multi-center clinical trial designed to assess the safety and performance of the OSSIOfiber® Hammertoe Fixation System. Trial results demonstrated fusion rates well above historical literature, dramatic improvements in pain and quality-of-life scores from baseline, radiographic evidence of good bio-integration with the surrounding anatomy, and no evidence of adverse biological response or serious adverse events associated with the OSSIOfiber® implant at six months follow-up. Additionally, all 25 patients that participated in the trial communicated high satisfaction rates with the OSSIOfiber® Hammertoe Fixation System and would recommend the technology to others. These findings will serve to support OSSIO’s Conformité Européene (CE) Mark application for approval of the OSSIOfiber® Hammertoe Fixation System later this year.

“These trial results are truly impressive and further validate the growing clinical and commercial evidence supporting the performance of the OSSIOfiber® Hammertoe Fixation System. The patients participating in the trial under my care have self reported a rapid return to full function and appreciate the fact that nothing permanent is left within the body following healing, providing them with further peace-of-mind,” said Dr. Luke Cicchinelli, co-principal investigator, Vigo, Spain. “The innovative OSSIOfiber® technology has ushered in a new era in orthopedic fixation – one that offers strong, secure fixation to restore full function and then allows the body to forget the implant ever existed.”

OSSIOfiber® Intelligent Bone Regeneration Technology can address many surgical applications through the manufacturing of endless implant designs, including nails, screws, anchors and plates. The company intends to pursue multiple applications in the distal extremity, trauma, sports, reconstruction, pediatrics, and spine segments. For more information on OSSIOfiber® please visit www.ossio.io.

About OSSIOfiber® Intelligent Bone Regeneration Technology

Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber® Intelligent Bone Regeneration Technology is a first-of-its-kind implant material stronger than cortical bone that leaves nothing permanent behind. OSSIOfiber® is engineered to provide the strength required for functional fixation and allows for full integration into the native anatomy without adverse biological response. OSSIOfiber® implants utilize existing reimbursement and surgical techniques. The OSSIOfiber® Hammertoe Fixation System and the OSSIOfiber® Bone Pin Family are cleared for use in the United States for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis and bone grafts in the presence of appropriate additional immobilization.

About OSSIO®

OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians and payors. Founded in 2014, its vision is to provide the first credible replacement to metal implants in the multi-billion-dollar global orthopedic fixation market with its OSSIOfiber® Intelligent Bone Regeneration Technology. OSSIO’s development headquarters is located in Caesarea, Israel, and its commercial headquarters is in Woburn, Massachusetts. For more information on the company visit www.ossio.io.

Forward-looking statements contained herein are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

For media inquiries, contact:
Kate Boes
919.995.5339
Kate.boes@gmail.com

OSSIO Secures $22 Million in Financing

Proceeds to Be Used for US Commercialization and Operational Expansion

WOBURN, MA., March 11, 2019 — OSSIO, an orthopedic fixation company, today announced the closing of $22 million in equity financings led by OCV Partners, a Los Angeles based venture capital firm, with continued participation from existing investors Ortho Vision LLC and Secocha Ventures.

OSSIO has raised a total of $35 million to date. The Company will use these funds to accelerate strategic growth initiatives, including talent acquisition, commercialization, new product development and operational expansion.

In January, OSSIO received 510(k) market clearance from the U.S. Food & Drug Administration for its OSSIOfiber™ Bone Pin Family, a first-of-its kind implant system that uses a proprietary bio-integrative material to provide stability and maintain the alignment of bone fractures, osteotomies, arthrodesis and bone grafts during the healing process, leaving no permanent hardware behind. Offering physicians and their patients a new category in fixation implants, the OSSIOfiber™ platform provides an unprecedented combination of mechanical strength and natural bone healing in a non-permanent implant. While OSSIOfiber™ will have broad application across the spectrum of orthopedic fixation, its first commercial use is focused in the foot and ankle segment for the treatment of forefoot conditions where hardware removal surgeries are prevalent.

“Following receipt of FDA clearance in January, we are moving forward with the commercial launch of OSSIOfiber™ in the United States. This financing provides us with the necessary capital to accelerate our core strategic growth initiatives to ensure we have the inventory and support to meet the anticipated demand for the OSSIOfiber™ technology,” said Brian Verrier, CEO, OSSIO. “We are honored that OCV, Ortho Vision and Secocha Ventures, together with the rest of our strong group of investors, stand behind our breakthrough fixation technology and our overall vision to transform the orthopedic experience for patients, physicians and payors.”

“OSSIO has created a novel bio-integrative fixation platform that we believe has the potential to disrupt the global orthopedic fixation market,” said Mark Yung, Co-Founder and Managing Principal, OCV Partners. “With its unparalleled bio-integrative platform and unique ability to address multiple surgical applications and segments, OSSIOfiber™ Intelligent Bone Regeneration Technology offers a highly differentiated fixation approach that is stronger than bone and fully incorporates into the native anatomy, minimizing implant-related complications and the need for additional surgeries.” Zohar Loshitzer, Principal at OCV, will be joining the OSSIO Board of Directors, effective immediately.

About OSSIOfiber™ Intelligent Bone Regeneration Technology

Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber™ Intelligent Bone Regeneration Technology is a first-of-its-kind implant material stronger than cortical bone that leaves nothing permanent behind. OSSIOfiber™ is engineered to provide the strength required for functional fixation and allows for full integration into the native anatomy without adverse biological response. OSSIOfiber™ implants utilize existing reimbursement and surgical techniques. The OSSIOfiber™ Bone Pin Family represents the first of several regulatory approvals for the company and is cleared for use in the United States for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis and bone grafts in the presence of appropriate additional immobilization.

About OSSIO

OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians and payers. Founded in 2014, its vision is to provide the first credible replacement to metal implants in the multi-billion-dollar global orthopedic fixation market with its OSSIOfiber™ Intelligent Bone Regeneration Technology. OSSIO’s development headquarters is located in Caesarea, Israel, and its commercial headquarters is in Woburn, Massachusetts. For more information on the company visit www.ossio.io.

About OCV Management LLC

OCV Management, LLC is a Los Angeles based investment firm co-founded by Richard Ressler and Mark Yung in 2016. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of 19 years. OCV invests in companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit www.ocvpartners.com.

Forward-looking statements contained herein are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Invoice2go Raises $10 Million, Attracting New and Existing Investors, and Hemi Zucker from OCV Partners to join the Board of Directors

REDWOOD CITY, Calif., Sept 11, 2018 — Invoice2go announces it has closed a $10 million equity round led by OCV Partners, with additional participation from existing investors Accel and Ribbit Capital. Hemi Zucker of OCV Partners joins the Invoice2go Board of Directors. Previously, as co-founder and CEO of j2 Global (JCOM), Zucker grew the organization into a global platform servicing 50+ markets. The new investment brings the total equity raised by Invoice2go to $60 million. The new funding fuels Invoice2go’s product innovation and rapidly growing offering for small businesses.

Invoice2go, the mobile invoicing app that gives small business owners and contractors control over their time and business, helps more than 250,000 customers around the globe send $24 billion in invoicing every year.

“Offering our customers a straightforward way to manage their business has fueled our mission from the beginning,” said Greg Waldorf, CEO of Invoice2go. “It’s this relentless dedication and unique approach to solving the challenges shared by small business all over the world that continues to attract not only investment, but momentum with the community we serve.”

Invoice2go will use the funding to accelerate its mission, and serve even more business owners with intuitive new ways to win jobs, track estimates and payments, and enable their customers to pay any way.

The company continues to significantly evolve the Invoice2go offering, releasing powerful, yet simple-to-use features that help business owners not only better manage their business, but also win more jobs, and grow as a result. The latest features released include Time Tracking, a seamless way to capture and bill for time, Appointments, a way to create and manage appointments on the go, and the ability to collect up front deposits.

“By understanding the true needs of their customers, Invoice2go has been able to build a powerful product that’s given more than 250,000 business owners the right mobile tools to stay on top of their business, and the confidence they are operating in the most professional, efficient way possible. We’re excited to join them on their mission to help even more people around the world not only manage, but meaningfully grow their business,” said Hemi Zucker, Managing Principal of OCV Partners.

About Invoice2go
Invoice2go is the mobile invoicing app that gives small businesses control over their time and business. Invoice2go gives its customers straightforward tools to track jobs, stay on top of payment status, and offer their clients the ability to pay any way so they can get the job done. The company was started by a small business owner who came from a family of tradespeople and wanted to help them streamline invoicing and getting paid. Today, Invoice2go’s popularity has spread around the globe, with more than 250,000 small business owners in 160+ countries using the app to send $24 billion in invoicing every year. For more information, visit invoice.2go.com.

OCV Management, LLC is a Los Angeles based investment firm co-founded by Richard Ressler and Mark Yung in 2016. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of 19 years. OCV invests in companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit www.ocvpartners.com.

Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs

DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was led by ArrowMark Partners and was joined by new investors Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Pontifax AgTech, OCV Partners, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, and entities affiliated with Leerink Partners. Existing investors venBio, F-Prime, RA Capital Management, Amgen Ventures, Osage University Partners, DUMAC, and the Longevity Fund also participated in the financing.

Precision intends to expand applications of its ARCUS genome editing platform in the areas of immuno-oncology, genetic disease, and food on its way to building a fully integrated biotechnology company. ARCUS is Precision’s proprietary, homing endonuclease-derived genome editing platform that leverages the small size and high specificity of a natural genome editing system. During 2018, Precision plans to utilize the proceeds from this financing to accelerate and expand its product portfolio. Specifically, Precision targets taking its lead, off-the-shelf CAR-T product into the clinic while advancing both its lead in vivo gene therapy program into IND-enabling studies and its flagship food program into field trials.

“We are thrilled to have such strong support from these leading healthcare investors who share in our vision for the future of human health through innovations in food and medicine,” said Matt Kane, CEO of Precision. “This financing provides us with a strong foundation from which we can advance our translational genome editing programs in multiple sectors.”

In conjunction with the Series B financing, Tony Yao of ArrowMark Partners has joined the Precision Board of Directors alongside existing directors Matt Kane, Derek Jantz, CSO of Precision, and Robert Adelman of venBio.

“We believe that Precision’s core gene editing technology represents a new way to alter the genome, and we are utilizing this technology to address several areas of great unmet need,” said Tony Yao, M.D., Ph.D. “I look forward to working with the team as we advance our programs.”

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP acted as outside counsel to Precision in connection with the financing.

About Precision BioSciences
Precision BioSciences is dedicated to improving life. Our mission is to cure genetic disease, overcome cancer, and feed the planet. We are striving to achieve this goal with ARCUS, our therapeutic-grade, naturally-derived genome editing system that combines both specificity and efficacy to help overcome life’s greatest genetic challenges. For additional information, please visit www.precisionbiosciences.com.

About OCV Management LLC
OCV Management, LLC is a Los Angeles based investment firm co-founded by Richard Ressler and Mark Yung in 2016. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of 19 years. OCV invests in companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit www.ocvpartners.com.